RU2642962C9 - Терапия болезни паркинсона с применением комбинации с фиксированными дозами - Google Patents

Терапия болезни паркинсона с применением комбинации с фиксированными дозами Download PDF

Info

Publication number
RU2642962C9
RU2642962C9 RU2014132940A RU2014132940A RU2642962C9 RU 2642962 C9 RU2642962 C9 RU 2642962C9 RU 2014132940 A RU2014132940 A RU 2014132940A RU 2014132940 A RU2014132940 A RU 2014132940A RU 2642962 C9 RU2642962 C9 RU 2642962C9
Authority
RU
Russia
Prior art keywords
pramipexole
weight
rasagiline
pellets
total weight
Prior art date
Application number
RU2014132940A
Other languages
English (en)
Russian (ru)
Other versions
RU2014132940A (ru
RU2642962C2 (ru
Inventor
Нурит ЛИВНАХ
Пнинит ЛИТМАН
Сарит ЗАКШ
Original Assignee
Фарма Ту Б Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48781101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2642962(C9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Фарма Ту Б Лтд. filed Critical Фарма Ту Б Лтд.
Publication of RU2014132940A publication Critical patent/RU2014132940A/ru
Publication of RU2642962C2 publication Critical patent/RU2642962C2/ru
Application granted granted Critical
Publication of RU2642962C9 publication Critical patent/RU2642962C9/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2014132940A 2012-01-12 2013-01-10 Терапия болезни паркинсона с применением комбинации с фиксированными дозами RU2642962C9 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261585824P 2012-01-12 2012-01-12
US61/585,824 2012-01-12
PCT/IL2013/050025 WO2013105092A1 (en) 2012-01-12 2013-01-10 Fixed dose combination therapy of parkinson's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2017146994A Division RU2771522C9 (ru) 2012-01-12 2013-01-10 Терапия болезни паркинсона с применением комбинации с фиксированными дозами

Publications (3)

Publication Number Publication Date
RU2014132940A RU2014132940A (ru) 2016-02-27
RU2642962C2 RU2642962C2 (ru) 2018-01-29
RU2642962C9 true RU2642962C9 (ru) 2018-05-04

Family

ID=48781101

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014132940A RU2642962C9 (ru) 2012-01-12 2013-01-10 Терапия болезни паркинсона с применением комбинации с фиксированными дозами

Country Status (21)

Country Link
US (1) US20150079187A1 (enExample)
EP (1) EP2802319B1 (enExample)
JP (1) JP6243351B2 (enExample)
KR (2) KR102276896B1 (enExample)
CN (1) CN104168896B (enExample)
AU (1) AU2013208653B2 (enExample)
CA (1) CA2860952C (enExample)
CY (1) CY1119793T1 (enExample)
DK (1) DK2802319T3 (enExample)
ES (1) ES2655676T3 (enExample)
HU (1) HUE038029T2 (enExample)
IL (1) IL233572B (enExample)
IN (1) IN2014MN01568A (enExample)
LT (1) LT2802319T (enExample)
MX (1) MX360409B (enExample)
NO (2) NO2802319T3 (enExample)
PL (1) PL2802319T3 (enExample)
PT (1) PT2802319T (enExample)
RS (1) RS56742B1 (enExample)
RU (1) RU2642962C9 (enExample)
WO (1) WO2013105092A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007235517B2 (en) 2006-04-03 2013-01-31 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Restless Legs Syndrome
CN104367565A (zh) * 2014-11-21 2015-02-25 哈尔滨圣吉药业股份有限公司 一种盐酸普拉克索缓释微丸
CN105147627B (zh) * 2015-08-19 2019-04-12 天津红日药业股份有限公司 一种含有盐酸普拉克索的药物组合物及其制备方法
CA3072994A1 (en) * 2017-08-17 2019-02-21 Zi-Qiang Gu Pamoate salt of monoamine anti-parkinson's agents, method of preparation and use thereof
WO2020127461A1 (en) * 2018-12-19 2020-06-25 Galecto Biotech Ab Amorphous form of 5-bromopyridin-3-yl 3-deoxy-3-[4-(3,4,5-trifluorophenyl)-1h-1,2,3-triazol-1-yl]-1-thio-alpha-d-galactopyranoside
US20230028539A1 (en) * 2019-12-06 2023-01-26 Shanghai Pharmaceuticals Holding Co., Ltd. Pharmaceutical composition, complementary kit and application thereof
WO2023112024A1 (en) * 2021-12-14 2023-06-22 Pharma Two B Ltd. Method of treating parkinson's disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009147681A1 (en) * 2008-06-06 2009-12-10 Pharma Two B Ltd. Pharmaceutical compositions for treatment of parkinson's disease
RU2394570C2 (ru) * 2004-02-20 2010-07-20 Новартис Аг Ингибиторы dpp-iv для лечения нейродегенерации и когнитивных расстройств
WO2011095973A1 (en) * 2010-02-03 2011-08-11 Pharma Two B Ltd. Extended release formulations of rasagiline and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040105740A (ko) * 2002-02-25 2004-12-16 엘란 파마슈티칼스, 인크. 염증 치료제의 투여 방법
JP2007518754A (ja) * 2004-01-22 2007-07-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング モノアミン神経伝達物質再取込みインヒビターとドーパミンアゴニストを含む医薬組成物
US20060018957A1 (en) * 2004-07-26 2006-01-26 Lerner E I Pharmaceutical dosage forms including rasagiline
AU2007235517B2 (en) * 2006-04-03 2013-01-31 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Restless Legs Syndrome
EP2150239A1 (en) * 2007-04-24 2010-02-10 Boehringer Ingelheim International GmbH Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
JP2012500283A (ja) * 2008-08-19 2012-01-05 ノップ ニューロサイエンシーズ、インク． （ｒ）−プラミペキソールを使用した組成物並びにその方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2394570C2 (ru) * 2004-02-20 2010-07-20 Новартис Аг Ингибиторы dpp-iv для лечения нейродегенерации и когнитивных расстройств
WO2009147681A1 (en) * 2008-06-06 2009-12-10 Pharma Two B Ltd. Pharmaceutical compositions for treatment of parkinson's disease
WO2011095973A1 (en) * 2010-02-03 2011-08-11 Pharma Two B Ltd. Extended release formulations of rasagiline and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
H. Reichmann. Initiation of Parkinson disease treatment // Journal of neurology. - 2007. - 13 (3). - P. 126-132. *
Hauser RA, Zesiewicz TA.Advances in the pharmacologic management of early Parkinson disease // Neurologist. - 2007. - May; 13(3). - P. 126-32. *
Hauser RA, Zesiewicz TA.Advances in the pharmacologic management of early Parkinson disease // Neurologist. - 2007. - May; 13(3). - P. 126-32. H. Reichmann. Initiation of Parkinson disease treatment // Journal of neurology. - 2007. - 13 (3). - P. 126-132. *
Raymond C Rowe, Paul J Sheskey, Marian E Quinn, Handbook of Pharmaceutical Excipients, No 6, 2009, P. 917, 20.06.1998. *

Also Published As

Publication number Publication date
EP2802319B1 (en) 2017-10-25
JP6243351B2 (ja) 2017-12-06
RS56742B1 (sr) 2018-03-30
NO2901008T3 (enExample) 2018-08-04
IL233572A0 (en) 2014-08-31
CN104168896B (zh) 2018-08-10
AU2013208653A1 (en) 2014-08-28
RU2017146994A (ru) 2018-10-22
LT2802319T (lt) 2018-04-10
RU2017146994A3 (enExample) 2021-03-16
KR20140138629A (ko) 2014-12-04
HUE038029T2 (hu) 2018-09-28
MX2014008537A (es) 2014-11-25
KR20200013791A (ko) 2020-02-07
PT2802319T (pt) 2018-01-29
ES2655676T3 (es) 2018-02-21
NO2802319T3 (enExample) 2018-03-24
MX360409B (es) 2018-10-30
RU2014132940A (ru) 2016-02-27
DK2802319T3 (da) 2018-01-29
IN2014MN01568A (enExample) 2015-05-08
RU2771522C2 (ru) 2022-05-05
WO2013105092A1 (en) 2013-07-18
EP2802319A1 (en) 2014-11-19
JP2015508411A (ja) 2015-03-19
AU2013208653B2 (en) 2017-04-20
RU2642962C2 (ru) 2018-01-29
HK1203847A1 (en) 2015-11-06
IL233572B (en) 2020-05-31
KR102276896B1 (ko) 2021-07-14
CY1119793T1 (el) 2018-06-27
CA2860952A1 (en) 2013-07-18
CN104168896A (zh) 2014-11-26
US20150079187A1 (en) 2015-03-19
PL2802319T3 (pl) 2018-04-30
CA2860952C (en) 2020-09-15
EP2802319A4 (en) 2015-07-01

Similar Documents

Publication Publication Date Title
JP6770564B2 (ja) ラサギリンの持続放出性製剤およびその使用
US10449159B2 (en) Methods and compositions particularly for treatment of attention deficit disorder
RU2642962C2 (ru) Терапия болезни паркинсона с применением комбинации с фиксированными дозами
MX2010005680A (es) Composiciones de tapentadol.
US11890261B2 (en) Composition and method for treating neurological disease
US10500170B2 (en) Composition and method for treating neurological disease
US9504657B2 (en) Fixed dose combination therapy of Parkinson's disease
RU2771522C9 (ru) Терапия болезни паркинсона с применением комбинации с фиксированными дозами
MXPA06011322A (es) Formas de dosificacion farmaceutica que tienen propiedades de liberacion inmediata y/o liberacion controlada que contienen un agonista del receptor gabab.
HK1203847B (en) Fixed dose combination therapy of parkinson's disease
CA3058933A1 (en) Tesofensine for reduction of body weight in prader-willi patients

Legal Events

Date Code Title Description
TH4A Reissue of patent specification